Pericyte-fibroblast transition promotes tumor growth and metastasis

Proceedings of the National Academy of Sciences of the United States of America

Volumn 113, Issue 38, 2016, Pages E5618-E5627

  Hosaka, Kayoko ^a   Yang, Yunlong ^a,b   Seki, Takahiro ^a   Fischer, Carina ^a   Dubey, Olivier ^a   Fredlund, Erik ^a   Hartman, Johan ^a   Religa, Piotr ^a   Morikawa, Hiromasa ^a   Ishii, Yoko ^c   Sasahara, Masakiyo ^c   Larsson, Ola ^a   Cossu, Giulio ^d   Cao, Renhai ^a   Lim, Sharon ^a   Cao, Yihai ^a,b,e  

^a KAROLINSKA INSTITUTE   (Sweden)

^b THE FIRST AFFILIATED HOSPITAL OF SHENZHEN UNIVERSITY   (China)

^c UNIVERSITY OF TOYAMA   (Japan)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e GLENFIELD HOSPITAL   (United Kingdom)

Author keywords

Fibroblast; Mesenchymal cell; Metastasis; PDGF; Pericyte

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; CALVASCULIN; IMATINIB; MESSENGER RNA; PLATELET DERIVED GROWTH FACTOR BB; SHORT HAIRPIN RNA; TUMOR MARKER; BECAPLERMIN; PDGFRB PROTEIN, HUMAN; PLATELET DERIVED GROWTH FACTOR B; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR;

ANGIOGENESIS; ANIMAL CELL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER ASSOCIATED FIBROBLAST; CANCER SURVIVAL; CELL EXPANSION; CELL STIMULATION; CIRCULATING TUMOR CELL; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; FIBROSARCOMA; GAIN OF FUNCTION MUTATION; GENE DELETION; GENE EXPRESSION PROFILING; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LEWIS CARCINOMA; LUNG CANCER; MALE; MESENCHYME CELL; METASTASIS; MOUSE; MYOFIBROBLAST; NONHUMAN; PERICYTE; PHASE TRANSITION; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; STEM CELL; TUMOR GROWTH; TUMOR INVASION; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG SCREENING; FIBROBLAST; GENETICS; KNOCKOUT MOUSE; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; RENAL CELL CARCINOMA; TUMOR CELL LINE; TUMOR MICROENVIRONMENT;

ANIMALS; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; FIBROBLASTS; HUMANS; MICE; MICE, KNOCKOUT; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; PERICYTES; PROTO-ONCOGENE PROTEINS C-SIS; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; TUMOR MICROENVIRONMENT; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84988736472     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1608384113     Document Type: Article

References (62)

1. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: The next generation. Cell 144(5):646-674.
2. Cao Y, et al. (2011) Forty-year journey of angiogenesis translational research. Sci Transl Med 3(114):114rv3.
3. Ferrara N, Kerbel RS (2005) Angiogenesis as a therapeutic target. Nature 438(7070):967-974.
4. Grivennikov SI, Greten FR, Karin M (2010) Immunity, inflammation, and cancer. Cell 140(6):883-899.
5. Mueller MM, Fusenig NE (2004) Friends or foes - Bipolar effects of the tumour stroma in cancer. Nat Rev Cancer 4(11):839-849.
6. Kalluri R, Zeisberg M (2006) Fibroblasts in cancer. Nat Rev Cancer 6(5):392-401.
7. Folkman J (2007) Angiogenesis: An organizing principle for drug discovery? Nat Rev Drug Discov 6(4):273-286.
8. Lim SD, et al. (2007) Expression of the neural stem cell markers NG2 and L1 in human angiomyolipoma: Are angiomyolipomas neoplasms of stem cells? Mol Med 13(3-4):160-165.
9. Govindarajan B, et al. (2012) Cooperative benefit for the combination of rapamycin and imatinib in tuberous sclerosis complex neoplasia. Vasc Cell 4(1):11.
10. Pillai VB, et al. (2015) Honokiol blocks and reverses cardiac hypertrophy in mice by activating mitochondrial Sirt3. Nat Commun 6:6656.
11. Armulik A, Genové G, Betsholtz C (2011) Pericytes: Developmental, physiological, and pathological perspectives, problems, and promises. Dev Cell 21(2):193-215.
12. von Tell D, Armulik A, Betsholtz C (2006) Pericytes and vascular stability. Exp Cell Res 312(5):623-629.
13. Crosby JR, Seifert RA, Soriano P, Bowen-Pope DF (1998) Chimaeric analysis reveals role of Pdgf receptors in all muscle lineages. Nat Genet 18(4):385-388.
14. Cao Y (2013) Angiogenesis and vascular functions in modulation of obesity, adipose metabolism, and insulin sensitivity. Cell Metab 18(4):478-489.
15. Dellavalle A, et al. (2011) Pericytes resident in postnatal skeletal muscle differentiate into muscle fibres and generate satellite cells. Nat Commun 2:499.
16. Hirschi KK, D'Amore PA (1996) Pericytes in the microvasculature. Cardiovasc Res 32(4):687-698.
17. Mills SJ, Cowin AJ, Kaur P (2013) Pericytes, mesenchymal stem cells and the wound healing process. Cells 2(3):621-634.
18. Tian X, et al. (2014) Vessel formation. De novo formation of a distinct coronary vascular population in neonatal heart. Science 345(6192):90-94.
19. Chen YT, et al. (2011) Platelet-derived growth factor receptor signaling activates pericyte-myofibroblast transition in obstructive and post-ischemic kidney fibrosis. Kidney Int 80(11):1170-1181.
20. Humphreys BD, et al. (2010) Fate tracing reveals the pericyte and not epithelial origin of myofibroblasts in kidney fibrosis. Am J Pathol 176(1):85-97.
21. Betsholtz C (1995) Role of platelet-derived growth factors in mouse development. Int J Dev Biol 39(5):817-825.
22. Lindahl P, Johansson BR, Levéen P, Betsholtz C (1997) Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science 277(5323):242-245.
23. Hosaka K, et al. (2013) Tumour PDGF-BB expression levels determine dual effects of anti-PDGF drugs on vascular remodelling and metastasis. Nat Commun 4:2129.
24. Bardeesy N, DePinho RA (2002) Pancreatic cancer biology and genetics. Nat Rev Cancer 2(12):897-909.
25. Heinrich MC, Blanke CD, Druker BJ, Corless CL (2002) Inhibition of KIT tyrosine kinase activity: A novel molecular approach to the treatment of KIT-positive malignancies. J Clin Oncol 20(6):1692-1703.
26. Savage DG, Antman KH (2002) Imatinib mesylate - A new oral targeted therapy. N Engl J Med 346(9):683-693.
27. Shah NP, Sawyers CL (2001) Recent success with the tyrosine kinase inhibitor STI-571 - Lessons for targeted therapy of cancer. Curr Opin Investig Drugs 2(3):422-423.
28. Sawyers CL (2002) Disabling Abl-perspectives on Abl kinase regulation and cancer therapeutics. Cancer Cell 1(1):13-15.
29. Gao Z, et al. (2005) Deletion of the PDGFR-beta gene affects key fibroblast functions important for wound healing. J Biol Chem 280(10):9375-9389.
30. Xue Y, et al. (2011) PDGF-BB modulates hematopoiesis and tumor angiogenesis by inducing erythropoietin production in stromal cells. Nat Med 18(1):100-110.
31. Kramann R, Humphreys BD (2014) Kidney pericytes: Roles in regeneration and fibrosis. Semin Nephrol 34(4):374-383.
32. Joyce JA, Pollard JW (2009) Microenvironmental regulation of metastasis. Nat Rev Cancer 9(4):239-252.
33. Pollard JW (2004) Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 4(1):71-78.
34. McCarty MF, et al. (2007) Overexpression of PDGF-BB decreases colorectal and pancreatic cancer growth by increasing tumor pericyte content. J Clin Invest 117(8):2114-2122.
35. Furuhashi M, et al. (2004) Platelet-derived growth factor production by B16 melanoma cells leads to increased pericyte abundance in tumors and an associated increase in tumor growth rate. Cancer Res 64(8):2725-2733.
36. Pietras K, Sjöblom T, Rubin K, Heldin CH, Ostman A (2003) PDGF receptors as cancer drug targets. Cancer Cell 3(5):439-443.
37. Crawford Y, et al. (2009) PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment. Cancer Cell 15(1):21-34.
38. Greenberg JI, et al. (2008) A role for VEGF as a negative regulator of pericyte function and vessel maturation. Nature 456(7223):809-813.
39. Pietras K, Pahler J, Bergers G, Hanahan D (2008) Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting. PLoS Med 5(1):e19.
40. Kuhnert F, et al. (2008) Soluble receptor-mediated selective inhibition of VEGFR and PDGFRbeta signaling during physiologic and tumor angiogenesis. Proc Natl Acad Sci USA 105(29):10185-10190.
41. Xian X, et al. (2006) Pericytes limit tumor cell metastasis. J Clin Invest 116(3):642-651.
42. Duda DG, et al. (2010) Malignant cells facilitate lung metastasis by bringing their own soil. Proc Natl Acad Sci USA 107(50):21677-21682.
43. Bergsten E, et al. (2001) PDGF-D is a specific, protease-activated ligand for the PDGF beta-receptor. Nat Cell Biol 3(5):512-516.
44. Cao R, et al. (2002) Angiogenesis stimulated by PDGF-CC, a novel member in the PDGF family, involves activation of PDGFR-alphaalpha and -alphabeta receptors. FASEB J 16(12):1575-1583.
45. LaRochelle WJ, et al. (2001) PDGF-D, a new protease-activated growth factor. Nat Cell Biol 3(5):517-521.
46. Li X, et al. (2000) PDGF-C is a new protease-activated ligand for the PDGF alpha-receptor. Nat Cell Biol 2(5):302-309.
47. Heinrich MC, et al. (2003) PDGFRA activating mutations in gastrointestinal stromal tumors. Science 299(5607):708-710.
48. Drummond-Barbosa DA, Vaillancourt RR, Kazlauskas A, DiMaio D (1995) Ligand-independent activation of the platelet-derived growth factor beta receptor: Requirements for bovine papillomavirus E5-induced mitogenic signaling. Mol Cell Biol 15(5):2570-2581.
49. Herrlich A, et al. (1998) Ligand-independent activation of platelet-derived growth factor receptor is a necessary intermediate in lysophosphatidic, acid-stimulated mitogenic activity in L cells. Proc Natl Acad Sci USA 95(15):8985-8990.
50. Lai CC, Henningson C, DiMaio D (1998) Bovine papillomavirus E5 protein induces oligomerization and trans-phosphorylation of the platelet-derived growth factor beta receptor. Proc Natl Acad Sci USA 95(26):15241-15246.
51. Karnoub AE, et al. (2007) Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 449(7162):557-563.
52. Liotta LA, Kohn EC (2001) The microenvironment of the tumour-host interface. Nature 411(6835):375-379.
53. Thiery JP, Acloque H, Huang RY, Nieto MA (2009) Epithelial-mesenchymal transitions in development and disease. Cell 139(5):871-890.
54. Dong M, et al. (2013) Cold exposure promotes atherosclerotic plaque growth and instability via UCP1-dependent lipolysis. Cell Metab 18(1):118-129.
55. Hedlund EM, et al. (2013) Tumor cell-derived placental growth factor sensitizes antiangiogenic and antitumor effects of anti-VEGF drugs. Proc Natl Acad Sci USA 110(2):654-659.
56. Nissen LJ, et al. (2007) Angiogenic factors FGF2 and PDGF-BB synergistically promote murine tumor neovascularization and metastasis. J Clin Invest 117(10):2766-2777.
57. Yang X, et al. (2013) Vascular endothelial growth factor-dependent spatiotemporal dual roles of placental growth factor in modulation of angiogenesis and tumor growth. Proc Natl Acad Sci USA 110(34):13932-13937.
58. Yang Y, et al. (2013) Anti-VEGF- and anti-VEGF receptor-induced vascular alteration in mouse healthy tissues. Proc Natl Acad Sci USA 110(29):12018-12023.
59. Cao R, et al. (2004) PDGF-BB induces intratumoral lymphangiogenesis and promotes lymphatic metastasis. Cancer Cell 6(4):333-345.
60. Cao R, et al. (2012) Collaborative interplay between FGF-2 and VEGF-C promotes lymphangiogenesis and metastasis. Proc Natl Acad Sci USA 109(39):15894-15899.
61. Dai M, et al. (2005) Evolving gene/transcript definitions significantly alter the interpretation of GeneChip data. Nucleic Acids Res 33(20):e175.
62. Wright GW, Simon RM (2003) A random variance model for detection of differential gene expression in small microarray experiments. Bioinformatics 19(18):2448-2455.